How The Parts Add Up: ISCG Headed For $54
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 02 2024
0mins
Should l Buy STTK?
Source: NASDAQ.COM
- Analyst Target Prices for ETFs: Analysts have compared the trading price of holdings in ETFs to 12-month forward target prices, with the iShares Morningstar Small-Cap Growth ETF (ISCG) having an implied analyst target price of $54.30 per unit.
- Upside Potential: ISCG is seen to have 20.59% upside potential based on average analyst targets of its underlying holdings, including Shattuck Labs Inc, Quanterix Corp, and Cullinan Therapeutics Inc.
- Notable Upside: Specific holdings like STTK, QTRX, and CGEM have significant upside potential according to analysts' target prices compared to recent share prices.
- Analyst Justification: Questions arise about whether analysts are justified or overly optimistic in their targets, prompting further investor research into the validity of these projections.
- Investor Considerations: High price targets relative to current trading prices can indicate optimism but may also lead to downgrades if not reflective of current company and industry developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STTK
Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.900
Low
4.00
Averages
5.00
High
6.00
Current: 3.900
Low
4.00
Averages
5.00
High
6.00
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Rating Upgrade: Piper Sandler initiates coverage on Shattuck Labs (STTK) with an Overweight rating and a $15 price target, likely driving an increase in the company's stock price.
- Clinical Trial Catalysts: Analyst Yasmeen Rahimi highlights that Shattuck's lead candidate SL-325 is set to report initial Phase 1 trial results in Q2 and initiate mid-stage trials in Q3, presenting significant market opportunities for the company.
- Mechanism Validation: The mechanism of action for SL-325 has been validated by nearly eight drugs targeting TL1A, a protein that causes inflammation through interaction with the DR3 receptor, which Shattuck's candidate aims to block, providing durable inflammation protection.
- Differentiated Treatment: The analyst notes that SL-325 offers a differentiated approach to treating inflammatory bowel disease patients, expected to have a greater inhibitory effect, thereby enhancing its competitive position in the market.
See More
- Mizuho Upgrades Applied Materials: Mizuho upgrades Applied Materials (AMAT) to Outperform from Neutral, raising the price target to $370, reflecting confidence in the semiconductor company's accelerating growth, which is expected to boost its stock price.
- Jefferies Downgrades BJ's Wholesale: Jefferies downgrades BJ's Wholesale from Buy to Hold, citing slower growth and increased risks in competitive markets, which may lead to underperformance and affect investor sentiment.
- Morgan Stanley Upgrades Johnson & Johnson: Morgan Stanley upgrades Johnson & Johnson (JNJ) to Overweight with a price target increase to $252, based on expectations of new product contributions and a higher P/E ratio, likely driving future earnings growth.
- Barclays Initiates TPG as Overweight: Barclays initiates TPG with an Overweight rating, highlighting its strong positioning for medium-term growth in a recovering capital markets environment, which is expected to attract more investor interest.
See More
- Analyst Upgrade: On December 1, H.C. Wainwright's Joseph Pantginis upgraded Shattuck Labs from neutral to buy with a price target of $6 per share, nearly triple its previous level, resulting in a nearly 74% surge in stock price.
- Drug Potential: Pantginis highlighted that SL-325, an investigational drug targeting inflammatory and immune-mediated disorders, is currently in clinical trials for irritable bowel syndrome (IBS) and has potential efficacy for multiple indications.
- Funding Support: In August, Shattuck closed a private funding round raising up to $103 million, which is expected to fund operations through 2029, providing crucial financial backing for its clinical-stage development.
- Financial Improvement: In Q3, Shattuck reduced its net loss to just over $10 million from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, indicating improved financial discipline within the company.
See More
- Analyst Upgrade: Joseph Pantginis from H.C. Wainwright upgraded Shattuck Labs to a buy rating on December 1, setting a price target of $6 per share, which catalyzed a nearly 74% surge in the stock price during December 2025, reflecting strong market confidence in the company.
- Drug Development Progress: Pantginis's positive outlook is largely based on SL-325, a first-in-class antibody drug targeting inflammatory and immune-mediated disorders, currently being evaluated for irritable bowel syndrome (IBS), with potential efficacy for multiple indications, heightening market expectations.
- Enhanced Funding Support: In August, Shattuck closed a private funding round raising up to $103 million, which is expected to fund operations through 2029, alleviating common financing concerns for clinical-stage biotech firms and bolstering investor confidence.
- Improved Financial Performance: In Q3, Shattuck reduced its net loss to just over $10 million under GAAP, down from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, indicating progress in cost management efforts.
See More
- Analyst Upgrade: Joseph Pantginis from H.C. Wainwright upgraded Shattuck Labs to a buy rating on December 1, setting a price target of $6 per share, which led to a nearly 74% increase in stock price in December, significantly boosting investor confidence.
- Drug Development Progress: SL-325, a first-in-class antibody targeting inflammatory and immune-mediated disorders, is currently undergoing clinical trials, with the FDA approving its IND application in August, indicating the company's potential in drug development and market prospects.
- Funding Support: In August, Shattuck closed a private funding round, raising up to $103 million, which will support its operations through 2029, alleviating the financing pressures typically faced by clinical-stage biotech firms.
- Improved Financials: The company reported a narrowed net loss of just over $10 million in Q3, down from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, demonstrating progress in cost management.
See More
- Executive Incentive Program: On December 10, 2025, Shattuck Labs granted 206,000 stock options to a newly hired non-executive officer at an exercise price of $3.23 per share, aimed at attracting top talent and enhancing leadership within the company.
- Stock Option Structure: The options have a maximum term of 10 years, with 25% vesting on November 17, 2026, and the remainder vesting in equal monthly installments over the following 36 months, ensuring long-term retention of the executive.
- Compliance and Transparency: The grant of stock options was approved by Shattuck's independent Compensation Committee, in accordance with Nasdaq Listing Rule 5635(c)(4), reflecting the company's commitment to compliance and transparency in executive compensation.
- Strategic Development Focus: Shattuck Labs is dedicated to developing innovative therapies for inflammatory and immune-mediated diseases, and this executive incentive measure will help attract talent with relevant expertise, driving further advancements in the biotechnology sector.
See More











